[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Ryu HJ, Hahn JS, Kim YS, Park K, Yang WI, Lee JD: Complete resolution of posttransplant lymphoproliferative disorder (diffuse large B-cell lymphoma) with reduction of immunosuppressive therapy. Yonsei Med J; 2004 Jun 30;45(3):527-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete resolution of posttransplant lymphoproliferative disorder (diffuse large B-cell lymphoma) with reduction of immunosuppressive therapy.
  • The treatment for PTLD is one of the most controversial topics in solid organ transplantation.
  • Early diagnosis and the early reduction in immunosuppression are essential even for monomorphic lymphoma.
  • We report here on a case of the complete resolution of PTLD (diffuse large B cell lymphoma) which occurred after a drastic reduction of immunosuppression in a renal transplant recipient.
  • [MeSH-major] Graft Rejection / drug therapy. Immunosuppressive Agents / administration & dosage. Kidney Transplantation. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Humans. Korea. Male. Remission Induction. Tomography, Emission-Computed. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15227742.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


2. Yoshii T, Horiguchi A, Shirotake S, Tobe M, Hayakawa M, Sumitomo M, Asano T: [Spontaneous rupture of the ureter as the primary symptom of malignant lymphoma]. Hinyokika Kiyo; 2010 Nov;56(11):639-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spontaneous rupture of the ureter as the primary symptom of malignant lymphoma].
  • We report a rare case in which upper ureteral rupture was the primary symptom of malignant lymphoma.
  • Computed tomography showed urinoma around the left kidney and retrograde pyelography showed a diffuse filling defect in the left ureter and a rupture of the upper portion of that ureter.
  • A urine cytology specimen from the left ureter was class V, suggesting undifferentiated carcinoma or malignant lymphoma.
  • An open laparotomy revealed a nodule on the omentum and diffuse fibrosis around both ureters, and the histopathological diagnosis was diffuse large B-cell lymphoma.
  • The patient' s ureteral stenosis disappeared after she received six cycles of R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone and rituximab) chemotherapy.
  • We should be aware that malignant lymphoma can be the cause of a spontaneous ureteral rupture.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / complications. Ureteral Diseases / etiology

  • Genetic Alliance. consumer health - Primary malignant lymphoma.
  • MedlinePlus Health Information. consumer health - Ureteral Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21187710.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Roldán-Valadez E, Ortega-López N, Cervera-Ceballos E, Valdivieso-Cárdenas G, Vega-González I, Granados-García M: Whole-body (18)F-FDG PET/CT in primary non-Hodgkin's lymphoma of the thyroid associated with Hashimoto's thyroiditis and bilateral kidney infiltration. Rev Esp Med Nucl; 2008 Jan-Feb;27(1):34-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole-body (18)F-FDG PET/CT in primary non-Hodgkin's lymphoma of the thyroid associated with Hashimoto's thyroiditis and bilateral kidney infiltration.
  • Due to the history of Hashimoto's thyroiditis and a rapid increase in size of the thyroid gland, diagnoses of thyroid lymphoma and anaplastic thyroid cancer were considered.
  • Fine needle aspiration was insufficient for diagnosis, and the product of thyroidectomy confirmed the diagnosis of diffuse large B-cell lymphoma.
  • A positron emission tomography/computed tomography scan was performed in our institution for staging, revealing nodal and extranodal metastasis.
  • Chemotherapy using cyclophosphamide, vincristine and dexamethasone (COP modified) led to a dramatic response of the tumor and a complete resolution of compressive symptoms.
  • [MeSH-major] Diagnostic Errors. Hashimoto Disease / radionuclide imaging. Kidney / pathology. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Positron-Emission Tomography. Thyroid Neoplasms / radionuclide imaging. Tomography, X-Ray Computed. Whole Body Imaging
  • [MeSH-minor] Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Female. Fluorodeoxyglucose F18. Goiter, Nodular / diagnosis. Humans. Radiopharmaceuticals. Remission Induction. Thyroidectomy. Thyroxine / therapeutic use. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18208780.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


Advertisement
4. Chia SC, Chau YP, Tan YM: Late-onset post-transplant lymphoproliferative disease presenting as massive occult gastrointestinal haemorrhage. Singapore Med J; 2008 May;49(5):e117-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a 56-year-old Chinese woman who developed PTLD 17 years after a renal transplant.
  • She initially presented with constitutional symptoms, and a diagnosis of diffuse large B-cell lymphoma was confirmed on liver biopsy.
  • Staging computed tomography demonstrated widespread adenopathy.
  • Initial treatment consisted of reduction of immunosuppression and Rituximab.
  • Prior to institution of chemotherapy, she presented with life-threatening melaena.
  • Histology confirmed necrotic diffuse large B-cell lymphoma and the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regime was subsequently commenced.
  • [MeSH-major] Gastrointestinal Hemorrhage / etiology. Jejunal Neoplasms / diagnosis. Kidney Transplantation. Lymphoma, Large B-Cell, Diffuse / diagnosis. Postoperative Complications


5. Ladha A, Haider G: Primary renal lymphoma. J Coll Physicians Surg Pak; 2008 Sep;18(9):584-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary renal lymphoma.
  • A 62-year-old male patient presented with right flank pain and right renal mass on CT scan.
  • Histopathology revealed a diffuse large cell B-cell lymphoma.
  • Patient presented again, with disseminated disease and was started on chemotherapy.
  • Although a rare disorder, missing primary renal lymphoma as one of the causes of renal mass can lead to disseminated disease and unnecessary nephrectomy, in spite of chemotherapy being standard management.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Cyclophosphamide. Doxorubicin. Humans. Male. Middle Aged. Nephrectomy. Prednisolone. Vincristine

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803901.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


6. Kusaba T, Hatta T, Tanda S, Kameyama H, Tamagaki K, Okigaki M, Inaba T, Shimazaki C, Sasaki S: Histological analysis on adhesive molecules of renal intravascular large B cell lymphoma treated with CHOP chemotherapy and rituximab. Clin Nephrol; 2006 Mar;65(3):222-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological analysis on adhesive molecules of renal intravascular large B cell lymphoma treated with CHOP chemotherapy and rituximab.
  • A 48-year-old man was admitted to our hospital for investigation of mild renal dysfunction.
  • Urinary examination revealed mild protein excretion (0.54 g/day) and microhematuria; renal biopsy revealed the focal proliferation of large mononuclear cells with mitosis in glomerular capillaries.
  • In electron microscopy, the glomerular capillary was filled with lymphoma cells and epithelial foot process fusion was noted.
  • Immunohistochemical analysis on adhesive molecules revealed a lack of CD11a expression on lymphoma cells, but positive CD54 expression on endothelial cells.
  • Systemic 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) revealed no abnormal uptake of isotopes.
  • On the basis of these findings, we diagnosed intravascular diffuse large B cell lymphoma localized in the kidney.
  • Despite treatment with rituximab and CHOP (prednisolone, doxorubicin, vincristine, cyclophosphamide) for 3 cycles at 1-month intervals, the renal dysfunction did not change.
  • In histopathological analysis of the second biopsy, lymphoma cells disappeared, but focal segmental glomerulosclerosis and moderate interstitial fibrosis were noted.
  • These pathological analyses let us conclude that a lack of CD11a could be a candidate factor for prevention of the extravasation of lymphoma cells from blood vessels in our patient.
  • We also presumed that the intraglomerular endothelial damage occurred due to chemotherapy-associated cell injury.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Adhesion Molecules / metabolism. Glomerular Mesangium / ultrastructure. Kidney Neoplasms / pathology. Lymphoma, B-Cell / pathology
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Biopsy. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Humans. Immunohistochemistry. Male. Microscopy, Electron. Middle Aged. Prednisone / therapeutic use. Rituximab. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550755.001).
  • [ISSN] 0301-0430
  • [Journal-full-title] Clinical nephrology
  • [ISO-abbreviation] Clin. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Cell Adhesion Molecules; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


7. Yanagihori H, Oyama N, Kawakami Y, Sakuma-Oyama Y, Nakamura K, Iwatsuki K, Kaneko F: A case of intravascular large B-cell lymphoma with multiple organ involvement. J Dermatol; 2003 Dec;30(12):910-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of intravascular large B-cell lymphoma with multiple organ involvement.
  • Intravascular large B-cell lymphoma (IVL) is a rare systemic disease characterized by clonal proliferation of neoplastic lymphoid cells within the capillary lumina of small blood vessels.
  • The confirmative diagnosis was based on the microscopic findings of the skin lesion with a B-cell immunophenotype.
  • Despite various clinical presentations, no neurological abnormality was observed until the patient died 12 months after the initial combination chemotherapy.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Female. Humans. Kidney Neoplasms / diagnosis. Kidney Neoplasms / drug therapy. Kidney Neoplasms / radiography. Kidney Neoplasms / secondary. Lung Neoplasms / diagnosis. Lung Neoplasms / drug therapy. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Middle Aged. Multiple Organ Failure. Neoplasm Metastasis. Skin Neoplasms / diagnosis. Skin Neoplasms / drug therapy. Skin Neoplasms / radiography. Skin Neoplasms / secondary. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14739519.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Blaes AH, Peterson BA, Bartlett N, Dunn DL, Morrison VA: Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer; 2005 Oct 15;104(8):1661-7
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial.
  • BACKGROUND: Posttransplant lymphoproliferative disorders (PTLD) remain an uncommon complication of solid organ transplantation with a high mortality rate reported after conventional therapies.
  • Alternative treatments such as rituximab have been explored.
  • The type of solid organ transplantation that these patients received included lung (five patients), kidney (four patients), heart (one patient), and kidney/pancreas (one patient).
  • The median time from transplantation to a PTLD diagnosis was 9 months (range, 1-122 mos).
  • Diagnostic B-cell histology was diffuse large cell lymphoma or polymorphous process.
  • Immunosuppressive therapy was decreased at the time of diagnosis.
  • The median time to treatment failure was 10 months (range, 5-25+ mos).
  • Four patients were alive at the time of last follow-up.
  • Further evaluation of rituximab in these disorders, potentially in combination with other therapies, is warranted.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Organ Transplantation / adverse effects. Postoperative Complications / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Male. Middle Aged. Prognosis. Rituximab. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society
  • (PMID = 16149091.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 40
  •  go-up   go-down


9. Verma S, Frambach GE, Seilstad KH, Nuovo G, Porcu P, Magro CM: Epstein--Barr virus-associated B-cell lymphoma in the setting of iatrogenic immune dysregulation presenting initially in the skin. J Cutan Pathol; 2005 Aug;32(7):474-83
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein--Barr virus-associated B-cell lymphoma in the setting of iatrogenic immune dysregulation presenting initially in the skin.
  • BACKGROUND: Epstein-Barr virus (EBV) has been implicated in B-cell lymphoma associated with iatrogenic immune dysregulation, primarily in the context of extracutaneous lymphoma.
  • METHODS: We describe six patients, five transplant recipients receiving cyclosporine and one patient with rheumatoid arthritis receiving methotrexate, who developed cutaneous presentations of EBV-associated B-cell lymphoma.
  • RESULTS: The cases comprised plasmablastic lymphoma (one case), plasmacytic marginal zone lymphoma (two cases), and diffuse large B-cell lymphoma (three cases).
  • Three patients responded to a reduction in the immunosuppressive regimen and antiviral therapy.
  • Recurrent disease developed in two, with one patient succumbing to multiorgan dissemination.
  • CONCLUSIONS: EBV-associated cutaneous B-cell lymphoma is characterized by a long interval between the initiation of immunosuppression and the development of lymphoma.
  • [MeSH-major] Epstein-Barr Virus Infections / immunology. Herpesvirus 4, Human / isolation & purification. Immunocompromised Host. Lymphoma, B-Cell / immunology. Skin Neoplasms / complications
  • [MeSH-minor] Adult. Aged. Arthritis, Rheumatoid / drug therapy. Arthritis, Rheumatoid / immunology. Diagnosis, Differential. Female. Humans. In Situ Hybridization. Kidney Transplantation / adverse effects. Kidney Transplantation / immunology. Male. Middle Aged. Postoperative Complications / chemically induced. Postoperative Complications / immunology. RNA, Messenger / analysis. RNA, Viral / analysis. Reverse Transcriptase Polymerase Chain Reaction. Thymidine Kinase / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008691.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Messenger; 0 / RNA, Viral; EC 2.7.1.21 / Thymidine Kinase
  •  go-up   go-down


10. Gotoh M, Kitahara T, Iguchi T, Izumi M, Mukai K, Ohyashiki K: [HIV-related multiple non-Hodgkin lymphomas]. Rinsho Ketsueki; 2008 Nov;49(11):1552-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He was HIV-positive, and had gastric diffuse large B-cell lymphoma and renal T-cell anaplastic large cell lymphoma (T-ALCL).
  • The patient received anti-retroviral therapy, and started the CHOP regimen for the double lymphomas, resulting in transient improvement.
  • However, fever again appeared during HAART and CHOP treatment, and a right inguinal subcutaneous lesion appeared.
  • Biopsy specimen demonstrated null cell ALCL, and this patient demonstrated multiple lymphomas.
  • [MeSH-major] Lymphoma, AIDS-Related / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, T-Cell / diagnosis. Neoplasms, Multiple Primary. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. Kidney Neoplasms / diagnosis. Kidney Neoplasms / drug therapy. Lymphocytes, Null. Male. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047787.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


11. Porcaro AB, D'Amico A, Novella G, Curti P, Ficarra V, Antoniolli SZ, Martignoni G, Matteo B, Malossini G: Primary lymphoma of the kidney. Report of a case and update of the literature. Arch Ital Urol Androl; 2002 Mar;74(1):44-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the kidney. Report of a case and update of the literature.
  • OBJECTIVES: To report on a case of primary renal lymphoma (PRL) and update the literature concerning this topic.
  • MATERIALS AND METHODS: A 48-year-old woman underwent surgery for the presumed diagnosis of renal cell carcinoma with bilateral adrenal metastases.
  • RESULTS: The neoplasm was assessed as primary renal non-Hodgkin high grade lymphoma, diffuse large B-cell type.
  • Unfortunately, 5 weeks later the patient was lost since missing chemotherapy and follow-up.
  • Several histogenetic theories of the disease have been postulated since the kidney does not normally contain lymphoid tissue.
  • Investigators reported many classes of non-Hodgkin lymphoma which include large, small, intermediate and mixed cell types with high, intermediate or low grade histologies.
  • The neoplastic lymphoid cells may express both B and T immunoblastic phenotypes, primary renal Hodgkin lymphoma has also been reported.
  • The disease may present with progressive renal failure of either oliguric or non oliguric type.
  • Imaging studies in diagnosing and staging primary renal lymphomas include ultrasound examination (US) and computed tomography (CT); there are also some reports of magnetic resonance imaging (MRI).
  • Renal biopsy is important in assessing the diagnosis of PRL as well as of acute renal failure for bilateral lymphomatous infiltration of the kidneys.
  • Up to now, there are no standard treatment modalities for this entity since the small number of cases reported.
  • Multidrug chemotherapy is mandatory for high grade lymphoma and when the disease is diagnosed preoperatively.
  • High dose chemotherapy in the future may offer a curative approach in primary bilateral renal disease and without end-stage renal disease.
  • Prognosis may be improved by early detection of disease and by performing systemic chemotherapy.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12053451.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone
  • [Number-of-references] 33
  •  go-up   go-down


12. Tadokoro J, Gunji H, Handa T, Aoyagi M, Nakamura Y, Saito K, Furusawa S: [Primary renal non-Hodgkin's lymphoma presenting as immune thrombocytopenia]. Rinsho Ketsueki; 2001 Jan;42(1):41-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary renal non-Hodgkin's lymphoma presenting as immune thrombocytopenia].
  • Computed tomography of the abdomen showed enlargement of the bilateral kidneys with multiple low-density areas, although neither lymphadenopathy nor hepatosplenomegaly was evident.
  • After amelioration of the thrombocytopenia by prednisolone therapy, open renal biopsy was performed and a diagnosis of diffuse large B-cell non-Hodgkin's lymphoma was made.
  • The patient achieved complete remission after CHOP therapy.
  • This was thought to be a rare case of primary renal non-Hodgkin's lymphoma initially presenting as immune thrombocytopenia, which was treated successfully by chemotherapy.
  • [MeSH-major] Kidney Neoplasms / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Thrombocytopenia / etiology

  • Genetic Alliance. consumer health - Immune thrombocytopenia.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11235133.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Kose F, Sakalli H, Mertsoylu H, Sezer A, Kocer E, Tokmak N, Kilinc F, Ozyilkan O: Primary renal lymphoma: report of four cases. Onkologie; 2009 Apr;32(4):200-2
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary renal lymphoma: report of four cases.
  • BACKGROUND: Although secondary renal involvement from systemic lymphoma is very frequent, primary renal lymphoma is a rare entity.
  • It is characterized by aggressive histopathology, very early extra-renal infiltration and poor prognosis.
  • CASE REPORTS: Here, we report 4 cases of primary renal lymphoma presenting with unilateral renal masses, which after radiological and clinical examination were assumed to be renal cell carcinoma.
  • 3 patients were diagnosed with Non-Hodgkin's lymphoma by nephrectomy and one patient was diagnosed by open renal biopsy.
  • Histopathological subtypes were diffuse large B cell lymphoma in 2 cases and non-Hodgkin's lymphoma of small B cell type in the others.
  • While 3 of the patients were treated with systemic chemotherapy, the fourth patient refused chemotherapy.
  • 2 patients (no. 2 and 3) were still in complete remission and were followed regularly in the second and first year after diagnosis, respectively.
  • CONCLUSIONS: Since it is difficult to diagnose primary renal lymphoma, most patients with this kind of tumor undergo radical nephrectomy, and diagnosis of primary renal lymphoma is delayed.
  • The authors believe that both the delayed diagnosis due to anatomical difficulties and the histological aggressive characteristics of this disease are equally responsible for the poor outcome in the case of primary renal lymphoma.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Kidney Neoplasms / therapy. Lymphoma / diagnosis. Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19372716.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


14. Sandrini S, Valerio F, Insalaco M: [Kidney transplantation and lymphomas]. G Ital Nefrol; 2010 Sep-Oct;27 Suppl 50:S46-50
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Kidney transplantation and lymphomas].
  • Post-transplant lymphoproliferative disease (PTLD) accounts for 30% of nonskin cancers after kidney transplants.
  • Diffuse large B-cell lymphoma is the most frequent form of PTLD.
  • The incidence of PTLD increases over time: from 1.2% at 5 years to 6.8% at 20 years.
  • Moreover, not only is it more frequent but also more serious than the early type because of the lower responsiveness to therapy.
  • During the first year after transplant, EBV-PCR monitoring can be helpful for the early diagnosis of EBV-associated PTLD, especially in children.
  • Interruption of immunosuppression is the first step of therapy, but it is rarely effective by itself.
  • Chemotherapy becomes essential in relapsed or refractory disease, but it significantly increases the risk of life-threatening infections.
  • The mortality rate is around 50% 12 months after diagnosis, often due to the side effects of chemotherapy.
  • [MeSH-major] Kidney Transplantation / adverse effects. Lymphoma / etiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20922695.001).
  • [ISSN] 0393-5590
  • [Journal-full-title] Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
  • [ISO-abbreviation] G Ital Nefrol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


15. Gorsane I, Bourkhis L, Laatiri MA, Aloui S, Letaif A, Haouala F, Ben Dhia N, Frih A, Zakhama A, Elmay M, Skhiri H: [Acute renal failure caused by renal lymphoma. A case report]. Nephrol Ther; 2010 Apr;6(2):132-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute renal failure caused by renal lymphoma. A case report].
  • Acute renal failure, as the initial manifestation of lymphoma, has been reported only in a few cases.
  • In this work, we report the case of a 28-year-old women admitted for acute renal failure.
  • Her physical examination detected bilateral kidney enlargement.
  • A 24-hour urine collection analysis allowed the detection of 1g of protein.
  • Renal ultrasound showed massively enlarged kidneys.
  • Renal biopsy of the kidney and pathologic examination showed diffuse infiltration of the interstitium with lymphocytes and atypical cells positive for CD20 markers.
  • A diagnosis of diffuse large B-cell type non-Hodgkin lymphoma was made.
  • However, investigations revealed the presence of two others sites of lymphoma: gastric and ophthalmic.
  • The patient's renal function and kidney size as well as the other lymphoma locations were normalized after the initiation of chemotherapy.
  • [MeSH-major] Acute Kidney Injury / etiology. Eye Neoplasms / diagnosis. Kidney Neoplasms / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Neoplasms, Multiple Primary / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antigens, CD20 / blood. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Diagnosis, Differential. Female. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Association Société de néphrologie. Published by Elsevier SAS. All rights reserved.
  • (PMID = 20299297.001).
  • [ISSN] 1872-9177
  • [Journal-full-title] Néphrologie & thérapeutique
  • [ISO-abbreviation] Nephrol. Ther.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Biomarkers, Tumor
  •  go-up   go-down


16. Shiratsuchi M, Suehiro Y, Yoshikawa Y, Ohshima K, Shiokawa S, Nishimura J: Extranodal multiple involvement of enteropathy-type T-cell lymphoma without expression of CC chemokine receptor 7. Int J Hematol; 2004 Jan;79(1):44-7
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal multiple involvement of enteropathy-type T-cell lymphoma without expression of CC chemokine receptor 7.
  • Enteropathy-type T-cell lymphoma (ETCL) is a rare extranodal lymphoma that tends to disseminate into the intestines and other extranodal organs.
  • We present a case of ETCL with involvement of the lungs and kidneys and report CC chemokine receptor 7 (CCR7) expression of lymphoma cells.
  • Histological examination of the resected specimen revealed diffuse proliferation of atypical large lymphoid cells.
  • The diagnosis was ETCL with dissemination into the lungs and kidney.
  • Lymphoma cells of the small intestine and in pleural effusion were CD3+, CD4+, CD7+, CD8-, CD25-, CD56-, CD103 +/-, and TIA-1+.
  • Rearrangement of the T-cell receptor beta gene was detected, and human T-lymphotropic virus was not integrated.
  • Combination chemotherapy did not result in a sustained response.
  • The results for CCR7 expression of lymphoma cells in the lung and pleural effusion were negative.
  • Therefore we concluded that lymphoma cells did not migrate into the lymph nodes but instead spread into the extranodal organs.
  • [MeSH-major] Lymphoma, T-Cell / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Movement. Cisplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Humans. Immunophenotyping. Intestinal Mucosa / pathology. Intestinal Neoplasms / pathology. Intestine, Small / pathology. Lymph Nodes / pathology. Male. Methylprednisolone / administration & dosage. Neoplasm Invasiveness. Neoplastic Stem Cells / pathology. Organ Specificity. Pleural Effusion / pathology. Prednisone / administration & dosage. Receptors, CCR7. Receptors, Chemokine. T-Lymphocyte Subsets / pathology. Vincristine / administration & dosage. Viscera / pathology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1992 Dec;141(6):1361-71 [1466400.001]
  • [Cites] Br J Haematol. 2000 May;109(2):258-66 [10848810.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):795-803 [10673521.001]
  • [Cites] Blood. 2000 Jan 1;95(1):30-8 [10607681.001]
  • [Cites] Cell. 1999 Oct 1;99(1):23-33 [10520991.001]
  • [Cites] J Biol Chem. 1997 Aug 1;272(31):19518-24 [9235955.001]
  • [Cites] J Biol Chem. 1997 May 23;272(21):13803-9 [9153236.001]
  • [Cites] Eur J Immunol. 2000 Mar;30(3):819-26 [10741397.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):708-12 [10537110.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2977-84 [11929789.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2473-5 [12642342.001]
  • [Cites] Immunity. 2001 Apr;14(4):377-86 [11336683.001]
  • (PMID = 14979477.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CCR7 protein, human; 0 / Receptors, CCR7; 0 / Receptors, Chemokine; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; VB0R961HZT / Prednisone; X4W7ZR7023 / Methylprednisolone; EPOCH protocol; ESAP protocol
  •  go-up   go-down


17. Zbiti N, Alhamany Z, Houssaini TS, Rhou H, Benamar L, Ezaitouni F, Bayahia R, Ouzeddoun N: [Acute renal failure due to malignant lymphoma infiltration]. Nephrol Ther; 2010 Dec;6(7):602-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute renal failure due to malignant lymphoma infiltration].
  • [Transliterated title] Lymphome rénal révélé par une insuffisance rénale aiguë.
  • We present two cases of renal lymphoma revealed by acute renal failure (ARF), which remains a rare clinical entity.
  • The diagnosis was a primitive kidney immunophenotype B lymphoma.
  • The patient died after three courses of chemotherapy due to rapid spread lymphoma.
  • The second case was a high-grade renal lymphomatous infiltration, with an unusual computer tomography image of two large kidneys compressing the stomach.
  • Death happened early before initiating therapy.
  • In both cases the diagnosis has been established by renal pathology.
  • Early diagnosis is a key component of therapeutic success, however, the rapid spread of lymphoma worsened renal and vital prognosis.
  • [MeSH-major] Acute Kidney Injury / etiology. Kidney Neoplasms / complications. Lymphoma, B-Cell / complications. Lymphoma, Large B-Cell, Diffuse / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Association Société de néphrologie. Published by Elsevier SAS. All rights reserved.
  • (PMID = 20920898.001).
  • [ISSN] 1872-9177
  • [Journal-full-title] Néphrologie & thérapeutique
  • [ISO-abbreviation] Nephrol. Ther.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


18. Turk HM, Ozet A, Ozturk M, Komurcu S, Kuzhan O, Arpaci F, Ozturk B, Safali M: Isolated renal relapse of a case with non-Hodgkin's lymphoma. Med Oncol; 2010 Jun;27(2):434-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated renal relapse of a case with non-Hodgkin's lymphoma.
  • Ten months later CT scan showed three hypodense masses in the right kidney.
  • Ultrasound guided renal biopsy revealed diffuse large B cell lymphoma.
  • Retrospective re-evaluation of the archival specimens of the mediastinal mass was also consistent with diffuse large B cell lymphoma.
  • After induction chemotherapy (four cycles of DHAP) she underwent high dose chemotherapy (BEAM) and autologous peripheral blood stem cell transplantation.
  • In conclusion, renal involvement during advanced lymphoma is quite common but isolated renal relapse in NHL is a rare situation.
  • Although renal infiltration generally shows a poor prognosis, long-term survival may be achieved with high dose chemotherapy and autologous peripheral blood stem cell transplantation.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Kidney Neoplasms / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adult. Female. Humans. Peripheral Blood Stem Cell Transplantation. Secondary Prevention

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2005 Jan;173(1):239 [15592087.001]
  • [Cites] Am J Surg Pathol. 1995 Feb;19(2):134-44 [7832273.001]
  • [Cites] Nephron Clin Pract. 2005;100(3):c86-91 [15824512.001]
  • [Cites] Urology. 1993 Sep;42(3):331-5 [8379037.001]
  • [Cites] Leuk Lymphoma. 2003 Oct;44(10):1733-8 [14692526.001]
  • [Cites] Hematol Oncol. 1990 Mar-Apr;8(2):105-10 [2344997.001]
  • [Cites] Cancer. 1996 Jun 1;77(11):2325-31 [8635103.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3783-5 [17704429.001]
  • [Cites] Turk J Pediatr. 1989 Jan-Mar;31(1):71-7 [2692261.001]
  • [Cites] Eur Urol. 1986;12(5):352-4 [3780803.001]
  • [Cites] Cancer. 1987 Aug 1;60(3):386-91 [3594375.001]
  • [Cites] Saudi J Kidney Dis Transpl. 2006 Sep;17(3):395-8 [16970262.001]
  • [Cites] Int Braz J Urol. 2006 Mar-Apr;32(2):190-2 [16650297.001]
  • [Cites] Clin Adv Hematol Oncol. 2008 Jul;6(7):527-31 [18654120.001]
  • [Cites] Tumour Biol. 2003 Aug-Sep;24(4):172-5 [14654710.001]
  • [Cites] Am J Nephrol. 1994;14(2):148-53 [8080008.001]
  • [Cites] Oncology. 1998 Sep-Oct;55(5):482-6 [9732229.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 Apr;21(4):487-92 [4007017.001]
  • [Cites] Gen Diagn Pathol. 1997 Feb;142(3-4):147-53 [9065578.001]
  • [Cites] Eur J Haematol. 2001 Sep;67(3):158-64 [11737248.001]
  • [Cites] Am J Kidney Dis. 1994 Oct;24(4):586-9 [7942815.001]
  • [Cites] J Natl Med Assoc. 2003 Mar;95(3):220-4 [12749682.001]
  • [Cites] J Surg Oncol. 1997 Mar;64(3):207-11 [9121151.001]
  • [Cites] Br J Cancer. 1994 Jul;70(1):154-9 [7517172.001]
  • (PMID = 19437146.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Hansen PB, Al-Farra G: [Treatment of central nervous system lymphoma following transplantation using monoclonal antibody and ganciclovir]. Ugeskr Laeger; 2010 Oct 18;172(42):2907-8
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of central nervous system lymphoma following transplantation using monoclonal antibody and ganciclovir].
  • [Transliterated title] Behandling af centralnervesystemlymfom efter transplantation med monoklonalt antistof og ganciclovir.
  • A 35-year-old female was diagnosed with a primary central nervous system posttransplant Epstein-Barr-virus-associated lymphoproliferative disorder three years after a renal transplantation.
  • The histological diagnosis of the brain tumour was a diffuse large B-cell lymphoma.
  • The patient had had diabetes mellitus for 28 years and was treated with four weekly doses of the monoclonal antibody rituximab, the antiviral drug ganciclovir and high-dose prednisolone, and the immune suppression was reduced.
  • After four weeks of treatment, a control magnetic resonance image showed complete regression of the central nervous system lesion.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Brain Neoplasms / drug therapy. Ganciclovir / analogs & derivatives. Kidney Transplantation / adverse effects. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents, Hormonal / therapeutic use. Drug Therapy, Combination. Epstein-Barr Virus Infections / etiology. Female. Humans. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / adverse effects. Prednisolone / administration & dosage. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21040668.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Antiviral Agents; 0 / Immunosuppressive Agents; 0 / valganciclovir; 4F4X42SYQ6 / Rituximab; 9PHQ9Y1OLM / Prednisolone; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


20. Halkos ME, Miller JI, Mann KP, Miller DL, Gal AA: Thoracic presentations of posttransplant lymphoproliferative disorders. Chest; 2004 Dec;126(6):2013-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transplanted organs included lungs (three patients), kidneys (three patients), kidney/pancreas (two patients), allogeneic bone marrow (two patients), and heart (one patient).
  • The time to presentation ranged from 1 to 97 months (median time, 8 months).
  • Six patients developed PTLD within 1 year of undergoing transplantation.
  • Diagnosis was achieved by CT-guided transthoracic needle biopsy in eight patients, and by open biopsy in three patients.
  • Pathologic analysis revealed monomorphic PTLD (ie, diffuse large B-cell lymphoma) in seven patients, polymorphic PTLD in two patients, anaplastic large cell lymphoma in one patient, and Hodgkin lymphoma in one patient.
  • All patients were initially treated with a reduction in immunosuppression therapy, and six patients (55%) received adjuvant chemotherapy.
  • Four patients died from complications of PTLD (kidney, two patients; heart, one patient; bone marrow, one patient), and three patients (all lung transplant recipients) died from rejection or infectious complications.
  • The median interval from diagnosis to death was 13 months (range, 1 to 42 months).
  • Heart and lung allograft recipients have the worst prognosis because of the mortality that accompanies rejection with subtherapeutic immunosuppression therapy.
  • Earlier diagnosis and improvements in immunosuppression and chemotherapy may improve survival for these inherently high-risk patients.
  • [MeSH-major] Lymphoproliferative Disorders / diagnosis. Thoracic Diseases / diagnosis. Transplantation / adverse effects
  • [MeSH-minor] Adult. Antibodies, Viral / analysis. Cytomegalovirus / isolation & purification. Female. Herpesvirus 4, Human / isolation & purification. Humans. Lymphoma / diagnosis. Lymphoma / etiology. Lymphoma / therapy. Lymphoma / virology. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Chest Injuries and Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15596707.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral
  •  go-up   go-down


21. Timurağaoğlu A, Uğur-Bilgin A, Colak D, Tuncer M, Gölbaşi I, Hazar V, Kiliçarsłan B, Undar L, Demirbaş A: Posttransplant lymphoproliferative disorders in transplant recipients. Transplant Proc; 2006 Mar;38(2):641-5
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidence of PTLD mainly depends on the transplanted organ, the immunosuppressive drugs, the viral serology, and the age of the recipient.
  • Among 1040 transplantations, including 931 renal, 14 heart, 55 liver and 40 allogeneic peripheral blood stem cell (PBSC), 8 patients (7 male, 1 female) were diagnosed with PTLD.
  • Five patients had undergone renal, one cardiac, one liver, and one PBSC transplantations.
  • According to the World Health Organization classification system, six patients were diagnosed as diffuse large B-cell lymphoma, one patient Burkitt's lymphoma, and one polymorphic PTLD.
  • At the time of diagnosis, 7 patients showed positive Epstein-Barr virus (EBV) and cytomegalovirus (CMV) Ig G and negative Ig M; one patient, positive EBV Ig M and negative CMV Ig G and M.
  • One of these patient's pathologic tissue revealed positive EBV DNA, which was not detected in six of the other eight patients.
  • This patient was an 8-year-old boy diagnosed with Burkitt's lymphoma at 31 months after liver transplantation.
  • Seven patients died of disease or complications of chemotherapy.
  • Only one patient survived after the diagnosis of PTLD.
  • In conclusion, even with treatment the mortality rate was high among our patients with PTLD.
  • [MeSH-minor] Adult. Child. Female. Heart Transplantation / immunology. Humans. Immunosuppressive Agents / therapeutic use. Incidence. Kidney Transplantation / immunology. Liver Transplantation / immunology. Male. Middle Aged. Stem Cell Transplantation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16549195.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


22. Egorova EK, Mar'in DS, Shutova NA, Galstian GM, Savenko TA, Kremenetskia AM, Kravchenko SK, Magomedova AU, Kovalenko AV, Kaplanskaia IB, Samoĭlova RS, Kliasova GA, Kozlova SIu: [Intensive chemotherapy of diffuse large B-cell lymphosarcoma in a female patient with chronic renal failure and afunctional left kidney]. Ter Arkh; 2008;80(7):57-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intensive chemotherapy of diffuse large B-cell lymphosarcoma in a female patient with chronic renal failure and afunctional left kidney].
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Failure, Chronic / complications. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Asparaginase / therapeutic use. Daunorubicin / therapeutic use. Diagnosis, Differential. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Severity of Illness Index. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Lymphosarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18763598.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


23. Boratyńska M, Smolska D: Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders. Transpl Int; 2008 Jun;21(6):605-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Kidney Transplantation / adverse effects. Lymphoproliferative Disorders / drug therapy. Protein Kinases / metabolism. Sirolimus / therapeutic use
  • [MeSH-minor] Adult. Epstein-Barr Virus Infections / diagnosis. Epstein-Barr Virus Infections / drug therapy. Epstein-Barr Virus Infections / etiology. Humans. Immunosuppressive Agents / therapeutic use. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / etiology. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / etiology. Male. Middle Aged. Signal Transduction / drug effects. TOR Serine-Threonine Kinases

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Nephrol Dial Transplant. 2007 May;22 Suppl 1:i27-35 [17456616.001]
  • (PMID = 18282244.001).
  • [ISSN] 0934-0874
  • [Journal-full-title] Transplant international : official journal of the European Society for Organ Transplantation
  • [ISO-abbreviation] Transpl. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; W36ZG6FT64 / Sirolimus
  •  go-up   go-down






Advertisement